We are pleased to share the completion of an undisclosed extended fundraising round for Gene Solutions. This round involved the issuance of a minority equity stake to August Global Partners Pte. Ltd. (AGP). This pivotal agreement was formalised at a Memorandum of Understanding signing ceremony on 9 January 2025 at the Singapore Exchange.
Established in 2017, Gene Solutions has emerged as a pioneering biotech company in Asia, recognised for its innovative oncology solutions and extensive clinical validation. The company has achieved commercial success in cell-free DNA testing across Southeast Asia and is expanding its product pipeline in cancer screening and personalised cancer care. This includes early cancer detection and monitoring tests, as well as collaborations with biopharma leaders to co-develop cancer therapeutics.
AGP is an independent fund management company specialising in healthcare investments, ranging from venture to growth-stage enterprises. Spun out from EDBI Pte Ltd, AGP manages significant assets in the healthcare sector. AGP's investment in Gene Solutions will not only provide financial backing but also harness its expertise in biotechnology and healthcare investments. Additionally, AGP’s network across the Asia Pacific region can play a crucial role in supporting Gene Solutions’ pursuit of pioneering healthcare advancements.
PwC Vietnam acted as the exclusive financial advisor to Gene Solutions throughout the fundraising round, with support from PwC Singapore’s Corporate Finance team. The team in Singapore assisted in preparing the financial model and facilitated Q&A sessions with Gene Solutions’ stakeholders.
